logo-loader
viewZacks Small-Cap Research

Zacks Investment Research analyst covers current trends in biotech industry

Zacks Investment Research Inc Biotechnology Analyst John Vandermosten speaks to Proactive Investors at the MicroCap Conference in New York. 

Vandermosten commented on Antares Pharma (NASDAQ:ATRS), and how the biotech's testosterone drug has just gained FDA approval.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

1 day, 1 hour ago

2 min read